TY - JOUR
T1 - Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone
AU - Roviello, Giandomenico
AU - Petrioli, Roberto
AU - Bonetta, Alberto
AU - Conca, Raffaele
AU - Rodriquenz, Maria Grazia
AU - Aieta, Michele
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The aim of this retrospective study is to evaluate the activity and safety of a steroidal switch from prednisone to dexamethasone in patients with advanced, heavily pre-treated, castration-resistant prostate cancer (CRPC) who progressed on abiraterone acetate. Treatment consisted of oral daily abiraterone plus dexamethasone (0.5 mg once daily) administered until disease progression or unacceptable toxicity. Thirty-six patients were evaluated: all men underwent a prior treatment with enzalutamide. A PSA decrease ≥50% was observed in 11% of patients; median progression-free survival was 10.8 weeks (95% CI: 9.2–16), and median survival was 17.6 weeks (95% CI: 15.8–28.8). Better efficacy and survival were observed in the subgroup of patients treated with abiraterone acetate prior for a period >3 months; treatment was well tolerated, and no grade 3–4 toxicities were observed. Our findings did not suggest the use of steroid switch in all CRPC who were heavily pre-treated. However, the switch could be an option for patients who responded well to prior abiraterone acetate treatment.
AB - The aim of this retrospective study is to evaluate the activity and safety of a steroidal switch from prednisone to dexamethasone in patients with advanced, heavily pre-treated, castration-resistant prostate cancer (CRPC) who progressed on abiraterone acetate. Treatment consisted of oral daily abiraterone plus dexamethasone (0.5 mg once daily) administered until disease progression or unacceptable toxicity. Thirty-six patients were evaluated: all men underwent a prior treatment with enzalutamide. A PSA decrease ≥50% was observed in 11% of patients; median progression-free survival was 10.8 weeks (95% CI: 9.2–16), and median survival was 17.6 weeks (95% CI: 15.8–28.8). Better efficacy and survival were observed in the subgroup of patients treated with abiraterone acetate prior for a period >3 months; treatment was well tolerated, and no grade 3–4 toxicities were observed. Our findings did not suggest the use of steroid switch in all CRPC who were heavily pre-treated. However, the switch could be an option for patients who responded well to prior abiraterone acetate treatment.
KW - abiraterone acetate
KW - dexamethasone
KW - prednisone
UR - http://www.scopus.com/inward/record.url?scp=85055751421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055751421&partnerID=8YFLogxK
U2 - 10.1007/s10637-018-0685-7
DO - 10.1007/s10637-018-0685-7
M3 - Article
C2 - 30345466
AN - SCOPUS:85055751421
VL - 36
SP - 1110
EP - 1115
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 6
ER -